[ad_1]
In fact, none of the NOACs currently available A situation that shows a pretty good effect. Although not quite the same, the NOAC effect and the security are similar.
Typically, older patients may be clbadified as high risk.
Among them, high-risk atrial fibrillation (NVAF) is badociated with the risk of bleeding or atrial fibrillation, the risk of falling and the restriction of patient compliance. & # 39 ;.
In May, Rivalroseban (Product name: Zarreto) was diagnosed with atrial fibrillation in patients with severe atrial fibrillation and atrial fibrillation The results of actual data on 10,754 people were followed for two years. As a result, Zarreto reduced the risk of stroke and systemic embolism by 32 percent and the risk of ischemic stroke by 31 percent compared with warfarin.
On the other hand, Dawson) did not significantly reduce the risk of stroke and systemic embolism compared to warfarin, and the incidence of major bleeding was similar to that of warfarin.
Apixaban was badociated with a high risk of critically ill atrial fibrillation Data was released to compete with weapons.
The results of the study showed that all rivers except one, with the exception of warfarin, apixaban and dabigatran, proved safe, the safest treatment it turned out to be apixaban. Of the four types of anticoagulants, including warfarin, apixaban has the lowest risk of ischemic stroke, intracranial hemorrhage and all-cause mortality.
Regarding drugs, apixaban had ischemic stroke, intracranial hemorrhage, Causes of death were respectively 1.3%, 0.5% and 1.5%. Rubaroxan ribavirin ratios were 1.9%, 0.9% and 4.5%, and warfarin was 1.5%, 1.3% and 4.6%, respectively. There is no clear standard for whether NOAC can be considered good. According to the 2018 KHRS A-Fib guidelines, NOAC selection and dose selection should be based on the individual characteristics of the individual patient, and there is no preferred NOAC in this case.
]
[ad_2]
Source link
